New device aims to heal stubborn diabetic foot sores
NCT ID NCT06003400
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tests a device called FITT on 20 people with hard-to-heal diabetic foot ulcers. The device combines several treatments to try to shrink the wound and ease pain. Researchers are checking if it is safe and if it improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FITT device (a combination therapy device for wound healing)
- What this could lead to
- If it works, this device could offer a new way to help heal stubborn diabetic foot ulcers and reduce pain.
- What could go wrong
- This is a very early, small trial with only 20 people. The device's exact method is secret, and it may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Jan 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males and females 18-80 years old * Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening * Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months. * Wagner classification stage 1 or 2 or post-debridement stage 3. * At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65 * Stable diabetic drugs 4 weeks before Screening * Be available for the entire study period, and be able and willing to adhere to protocol requirements * Provide written informed consent prior to admission into the study Exclusion Criteria: * Have a glycosylated hemoglobin (HbA1c) \> 10.5% * Have more than one wound * Have a body mass index (BMI) \> 40 kg/m2 * Have visible bone exposure at wound site * Anemia (Hemoglobin \< 9 g/dL) or White Blood Cells count \> 11,000/μL or Platelets count \< 100,000/μL or liver function tests \> 3 times upper normal lab values or Creatinine \> 3 mg/dL; any indication of malnourishment (Albumin \< 3 g/dL); INR\>2 or any other clinically significant blood and urinalysis tests per the physician's discretion * Patients with unstable hypertension * Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period * Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years, not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test * Participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study * Patients with active Gangrenous foot ulcers * Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis) * Patients with uncontrolled hyperthyroidism * Patients with history of collagen diseases * Patients with known allergy to ozone * Anxiety, Depression, history of Mental illness or patient under Guardian * Any medical condition for which the investigator deems the subject unable to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic foot ulcer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hilel Yafe Medical Center
Hadera, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy shots aim to save legs from amputation in diabetes
- New wound dressing put to the test against diabetic foot ulcers
- Silver and sound: can ultrasound push nanoparticles into diabetic wounds?
- Zapping a leg nerve: can a wearable device help stubborn ulcers heal?
- Wound dressings that trap microbes: scientists test a Drug-Free approach
- Can a traditional herbal mix save limbs from diabetic ulcers?